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Abstract Bovine globin has been incubated with mice peritoneal 
macrophages in order to study its hydrolysis by lysosomal 
enzymes, among which chiefly cathepsin D. Analysis of resulting 
peptides, by reversed-phase high-performance liquid chroma- 
tography (RP-HPLC), shown the release of a bioaetive peptide, 
VV-hemorphin-7. When a carboxyl proteinase inhibitor such as 
pepstatin A was added, no hemorphin was generated. Our results 
clearly demonstrated that VV-hemorphin-7 generation was 
principally due to cathepsin D. This study allowed us to 
hypothetize a possible pathway for in vivo hemorphins appear- 
ance from globin catabolism by macrophages. 
£ey words: Homorphin; Hemoglobin; Macrophages; 
Lysosomal enzymes; Cathepsin D; High-performance liquid 
chromatography 
1. Introduction 
A few years ago, biologically active peptides with affinity 
for opioid receptors were isolated and purified in vitro, from 
enzymatically treated hemoglobin and in vivo in biological 
fluids. Because of their origin (hemoglobin), these peptides 
have been called hemorphins. 
The first two hemoglobin-derived peptides identified in vitro 
and termed hemorphin-4 (Tyr-Pro-Trp-Thr) and hemorphin-5 
(Tyr-Pro-Trp-Thr-Gln) were obtained by treatment of bovine 
blood with gastrointestinal enzymes. These amino acid se- 
quences corresponded to the 34-Y/ and 34-38 fragments of 
the bet~-chain of bovine hemoglobin and 35-38 and 35-39 
fragments of the beta-chain of human hemoglobin [I]. More 
recently, two additional opioid peptides corresponding to the 
sequence 32-40, VaI-Val-Tyr-Pro-Trp-Thr-GIn-Arg-Phe (VV- 
hemorphin-7) and 31-40, Leu-VaI-Val-Tyr-Pro-Trp-Thr-Gln- 
Arg-Phe (LVV-hemorphin-7) of the beta-chain of bovine he- 
moglobin have also been isolated in vitro from a bovine he- 
moglobin peptic hydrolysate [2]. 
Concurrently, some similar active peptides have been iden- 
tified in the organism. Indeed, LVV-hemorphin-4, designated 
spinorphin (Leu.VaI-VaI-Tyr-Pro-Trp-Thr), has been isolated 
from bovine spinal cord by Nishimura and Hazaro [3]. In 
their report, an inhibitory activity of spinorphin toward 
some enkephalin-deg~ading e zymes was demonstrated, sug- 
gesting that this substance should be an in rive neuromodu- 
later. During the extraction and purification of a tetrapeptide, 
the Tyr-Mif-I from bovine hypothalamic tissue, another pep- 
tide was identified as Val-Val-Tyr-Pro-Trp-Thr-Gln showing 
homology with residues 32-38 of the beta-chain of bovine 
hemoglobin. This peptide was called valorphin [4]. Another 
opioid peptide (LVV-hemorphin-6) was isolated from fresh 
frozen human pituitaries by Gliimsta et al. [5]. Its primary 
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structure (Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg) was identi- 
cal to fragment 32--40 of the beta-chain of human hemoglo- 
bin. The same authors described the presence of LW-hemor- 
phin-7 in cerebrospinal fluid (CSF) of patients with 
cerebrovascular bleeding [6], and hemorphin-7 in human plas- 
ma after long distance running [7,8]. Many other fragments of 
the beta-chain of hemoglobin have also been identified in rive 
[9]. 
Concerning the biological properties of hemorphins, their 
opioid activity was demonstrated by the use of electrically 
stimulated myenteric plexus/longitudinal muscle preparation 
of the guinea-pig ileum (GPl) [10]. In this bioassay, hemor- 
phins led to the inhibition of electrically induced GPI contrac- 
tions. This inhibition was reversed by the specific opioid an- 
tagonist, naloxone [11,12]. In addition to this effect, the 
hemorphins exhibit inhibitory action on angiotensin convert- 
ing enzyme [13,14]. Another interesting feature of some he- 
morphins is their effect on 13-endorphin release from the pi- 
tuitary [15]. Moreover, Davis et al. reported that hemorphin-4 
and -5 could exert in rive effect on central nervous ystem: 
antinociception, inhibition of gastrointestinal propulsion or 
inhibition of the volume-induced spontaneous micturition re- 
flex [16]. 
It can be noticed that the above-mentioned hemorphins, 
whatever their source, originated from the same region of 
the beta-chain of hemoglobin (residues 32-41 of human and 
31-40 of bovine hemoglobins) [2,17]. These data suggested 
that hemoglobin could be a precursor of biologically active 
peptides, and that hemorphins could be generated in the or- 
ganism during physiological (catabolism of red cells) or phys- 
iopathological (inflammation) hemoglobin proteolysis [2,6,17]. 
In any case, the actual site of hemorphins generation in the 
organism is still not elucidated. 
In the present work, we were interested to determine the 
possible way of natural generation of hemorphins in the or- 
ganism. According to the: fundamental knowledge of the phys- 
iology of macrophages and their role in the cellular catabo- 
lism and/or in the inflammatory process, we have investigated 
the appearance of hemorphins when hemoglobin is submitted 
to the action of macrophage acidic lysosomal proteases. Thus, 
bovine globin was incubated with mice peritoneal macro- 
phages. The hydrolysis was followed using UV.spectrophoto- 
metry, and high-performance liquid chromatography (HPLC) 
coupled with photodiode array detection was performed in 
order to detect he hemorphins generated uring the incuba- 
tion [18]. 
2. Materials and methods 
2.1. Materials and chemicals 
UV-absorbance was monitored with a Perkin Elmer lambda 16 
spectrophotometer. HPLC analyses were performed with a Waters 
600 automated gradient controller-pump odule, a Waters wisp 717 
automatic sampling device and a Waters 996 photodiode array detec- 
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Fig. i. Protcolytic degradation of globin by macrophages after 24 h 
incubation and the effects of acidic protease inhibitors, leupeptin 
and pepetatin A. Globin (10 mg/ml, citrate buffer pH 3.51 was incu- 
bated with mam'ophages monolayer in the absence of glucose (A-24 
hi, in the presence of glucose ! g/I (B--24 hi, in the presence of glu- 
cose I g/! and leupeptin :SO ;tM ((::-24 hi, in the presence of glucose 
I g/I and pepetatin A (D-24 hi. After incubation, the absorbance of 
the trichloroaceti¢ acid soluble fractions was measured. TI, T2 and 
T3, control experiments: cells alone, cells with globin without incu- 
bation, and globin alone respectively.Mean :1: S.E.M., n "-" 4. 
tor (Milford, USA). The MUlenium software was used to plot, acquire 
and treat spectral and chromatographic data, A comparison of the 
UV-spectra (200 to 350 nm) of each peak in the chromatographic 
profiles with standard hemorphin-7, VV. and LVV-hemorphin-7 spec- 
tra (library spectra) was performed uring analyses. Standards and 
samples were chromatographed at room temperature on a Nova-Pak 
C-18 column. Spectrum matching results were reported by Waters 
Millenium as Match Angle (MA) and Match Threshold (MT). MA 
is a measure of the difference in spectral shapes between an unknown 
spectrum and a library spectrum. MA can range from 0 to 90 degrees. 
it was found that at lower MA, the spectra were similar, as previously 
reported [18]. MT described the sensibility of the measure. It can 
range from 0 to 180 degrees. Larger values indicate a lower sensibility 
of the measure. If the MA is greater than the MT, the two spectra re 
different [18]. 
Amino acids were analysed using a Waters Picotag work station. 
Bovine globin, leupeptin, pepetatin A were obtained from Sigma 
Chemicals Company (Lyon, France). Resazurin Thioglycollate was 
purchased from Sanofi Diagnostics Pasteur (Marues la Coquette, 
France). MEM-E (Minimum Essential Media Eagle), I.-glutamine 
200 raM, antibiotics (10000 IU/ml penicillin, 10 mg/ml streptomycin) 
and fetal calf serum were provided by ATGC Biotechnologle (Paris, 
France). Hemorphin.7, VV- and LW-hemorphin.7 were synthesized 
by C. Guillon, Laboratoire de Technologle Enzymatique, University 
of Compi~gne (Compii~lne, France). 
All other chemicals and solvents were of analytical grade from 
commercial sources, 
Z2. MacropAage c, ltur¢ 
Macropbnges were isolated from the peritoneal cavity of female 
DBFI mice (2S-30 g) Specific Pathogen Free (SPF) following a sterile 
peritonitis, For this, 1,5 ml of Resazurin Thioglycollate was injected 
intraperitoneally into each animal, A sterile inflammatory agent such 
as thioglycollate broth elicits an influx of 10-fold more macrophages 
into the peritoneal cavity, starting within I day and reaching a peak 
after 3--5 days [19], in addition, the contents and the specific activities 
of lysosomal hydrolases were higher in cells from thioglycollate-trea, 
ted mice than in those from untreated mice [20], After 4 days, the mice 
were killed by cervical dislocation, The peritoneal cavity was washed 
with 5 ml 0,2 M phosphate-buffered saline pH 7,4 (PllS). The perito- 
neal cells obtained in a single experiment (5 mice) were collected by 
ceutrifngation at400×g for 10 rain at 4ec, Macrophages, identified 
by measuring neutral red uptake, were counted under phase contrast 
microscopy, The predominant cell type in such peritoneal exudates i
the macrophage c ll [21]. About l0 T cells per mouse were obtained 
and 80% were macrophnges. 
Purification of macrophages was based on their ability to adherate 
on culture support. After ceutrifugation, the cell pellet was resus- 
pet~ded in PIlS containing both M8 a+ and Ca 2+ and the cells were 
incubated in 6-well plates (Falcon) at a density of 4× 106 macro- 
t~hag~s~well in 2 ml of PBS. The incubation was performed at 37°C 
for 3 h ~o. a humidified atmosphere of 5% CO2 and 95% air, Ca 2+ and 
Mg 2+ we, re used as adherence-promoting factors [22]. Non-adherent 
cells were removed by washing and macrophages were then incubated 
for 4 days in 2 ml of MEM-E containing 10% fetal calf serum, 20 IxM 
L-glutamine and antibiotics (100 IU/ml penicillin, 100 Ixg/ml strepto- 
mycin). After 4 days, the macrophages were used in experiments. 
2.3. Giobin hydrolysis 
Globin hydrolysis was performed in 0.1 M sodium citrate buffer pH 
3.5 according to Carraway et al. [23]. 
The ability of macrophages to hydrolyse globin was determined as 
follows. Bovine globin was diluted in citrate buffer pH 3.5 (10 mg 
globin/ml) containing 100 Ullml penicillin and 100 Itg/ml streptomy- 
cin (Solution A). In order to investigate its putative ffect, 1 mg/mi 
glucose was added to solution A (Solution B). In some experiments, 
inhibitors of the lysosomal proteases were added in order to charac- 
terize which lysosomal proteases should be implicated in globin hy- 
drolysis. Leupeptin (Solution C) or pepstatin A (Solution D) were 
assayed at a final concentration of 50 ~tM. The adherent cells were 
washed twice before use. Macrophage monolayers were incubated 
with I ml of each solution (A to D) at 37°C in humidified atmosphere 
of 5% CCYz during 24 h. The incubation was stopped by adding 2 ml 
of a 12% trichloroacetic a id (TCA) solution. The iysate was then 
centrifuged at 5000 rpm for 15 min and the pellet was removed, 
The absorbance of supematants was measured at 280 nm, Three con- 
trois were carried out: cells alone (TI), cells with globin without 
incubation (T2) and globin alone (T3), 
2. 4. Reversed.phase high.performance liquid chromatography 
(RP.HPLC) 
The supematants were resolved on a Waters Nova-Pak silica gel C- 
18 column (3.9× 150 mm). The mobile phase comprised 10 mM am. 
monium acetate buffer pH 6.0 as eluent A and acetonitrile as eluent B. 
The flow rate was !.5 ml/min. The pH of each TCA-supernatant was 
adjusted to 6.0 with ! M NH4OH and filtered through 0.22 Itm filters. 
Then, 30 ttl of each sample was injected. On the other hand, synthetic 
VV-hemorphin-7 (0,5 mg in 30 pl) was co-injected in the same con- 
ditions with each supernatant sample. The gradient applied was 0o/o to 
30% of eluent B in 40 min. Between each run, the column was equili- 
brated with 100% of eluent A tbr 10 min. UV-absorbance was mon- 
itored at 215 nm and 280 rim. Hemorphin-7, W-  and LVV-hemor- 
phin-7 were searched in each eluted peak using the UV-spectra 
comparison method eveloped by Zhao et al. [18]. Each hemorphin. 
related peptide was collected and freeze-dried before amino aci~ anal- 
ysis. 
2.S. Amino acid analysis 
Peptide hydrolysis was achieved with constant.boiling 6 M HCI 
containing I% phenol, for 24 h at 109°C. Precolumn derivatization 
of amino acids with phenyl isothiocyanate and HPLC separation of 
derivatized amino acids on a Waters RP-Picotag column (3.9 × 150 
ram) were performed according to Bidlingmeyer tal. [24]. The detec- 
tion wavelength was 254 nm and the flow rate I ml/min. All aqueous 
HPLC eluants were filtered prior to use on Millipore system filtration 
with 0.22 pm filters and degassed with helium during analysis. 
2.6. Mass spectrometry analysis 
Mass spectra, generated from FAB mass spectrometry of the active 
peptide, were recorded on a four-sector "Concept Ir '  tandem mass 
spectrometer (Kratos, Manchester, UK). Ions were produced in a 
standard FAB source by bombarding the sample with xenon atoms 
--4, 
Fig. 2. Reverse phase HPLC of TCA soluble fractions from samples 
A-24 h, 13-24 h, C-24 h, D-24 h and T2 ,:ontrol experiment. UV- 
absorbance was monitored at 215 nm and 280 rim. Hemorphins 
were Iocalised by UV-spectra comparison after separation of TCA- 
supernatants on a Nova-Pak C-18 column. TCA-supernatants were 
filtered through 0.22 pm filters and 30 ~tl were applied to the col- 
umn. The gradient was 0% to 30% of eluent B in 40 rain at a flow 
rate of 1.5 ml/min. An aliquot of hemorphin-like peaks was col- 
lected for the amino acid composition analysis. The same profile as 
T2 was obtained for TI and T3 control experiments. 
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Fig. 3. HPLC co-elution profile of synthetic VV-hemorphi,-7 (VV- 
H7) with hemorphin-like p ak from sample C-24 h. Chromato- 
graphic onditions were the same as in Fig. 2. 
having a kinetic energy of 8 KeV and the instrument was operated at
an accelerating voltage of 8 KV. The peptide was dissolved in water 
(250 pg in 50 ttl) and i ttl of the solution was loaded on the stainless 
steel tip with thioglycerol as matrix. The mass range was scanned at 
10 s/decade with a mass resolution of 3000. Caesium iodide was the 
standard for mass calibration. 
3. Results and discussion 
The absorbances at 280 nm of TCA-supematants from 
samples incubated 24 h in the absence or presence of inhibi- 
tots, are displayed in Fig. 1. These results clearly showed a 
proteolytic activity due to macrophage c lls. After incubation 
of macrophages with globin and without inhibitor, a strong 
increase of the absorbance indicated the presence of a large 
amount of peptides in the supernatants (A-24 h, B-24 h). No 
significant difference was noticed with (A-24 h) or without 
(B-24 h) glucose in the incubation media. In the absence of 
macrophage cells (T3), a very low absorbance was observed 
after 24 h incubation showing that the cells were crucial for 
the proteolytic activity. Moreover, in the absence of bovine 
globin (TI), a very low absorbance was also obtained suggest- 
ing the lack of hydrolysis of any other proteinic substrata. 
Experiments carried out in the presence of enzyme inhibitors 
were both characterized by a decrease of absorbance at 280 
nm, However, in the presence of leupeptin (C-24 h), the de- 
crease was less significant han with pepstatin A (D-24 h). 
The presence of leupeptin induced about 28% inhibition of 
the proteolytic activity (C-24 h), As far as pepstatin A is 
concerned, a complete inhibition was observed since the ab- 
sorbance was reduced by 100% (D-24 h). The present obser- 
vations, for both inhibitors, are in agreement with an earlier 
Table I 
Spectrum atching results obtained from the UV-spectra compari- 
son 
RT' MA MT Name' ' 
A=24 h 33.877 0,629 1.238 VV-hemorphin-7 
~24 h 33,838 0,593 1,376 VV-hemorphin,7 
C~24 h 33,867 0323 !, 133 VV-hemorphin-7 
During chromatographic analysis on a Nova-Pak C-18 column of 
"rCA SUlX'matants, he Match Angle (MA) and Match Threshold 
(Mr) were calculated by Millenium system from the comparison jf
UV-spectra of synthetic hemorphins with each eluted peak. 
"Retention time (rain), 
"'Given by Millenium software to the peak after UV-comparison. 
report about the proteolytic activity of leukocyte(s) proteases 
and cathepsin D [25]. It was demonstrated that a biologically 
active xenopsin-related peptide was generated from liver ex- 
tracts by these enzymes. Pepstatin A has been used as a potent 
inhibitor of acidic proteases and was shown to be a strong 
inhibitor of the pepsin-like acid protease, cathepsin D. In 
addition, leupeptin has also been demonstrated to inhibit ca- 
thepsin D activity but to a lesser extent [25]. Our results al- 
lowed us to speculate about the ability of macrophage acidic 
proteases, and chiefly cathepsin D, to hydrolyse globin. 
The UV-profiles obtained from fractionation of TCA- 
supernatants on a C-18 Nova-Pak column are shown in Fig. 
2. The resolution of each sample was achieved in less than 40 
min. The efficiency of this one-step separation allowed easy 
on-line detection of hemorphins using the UV-spectra com- 
parison method recently developped by Zhao eta!. [18]. This 
method allowed the detection of an hemorphin-like peak 
among many other peaks in samples A-24 h, B-24 h, and 
C-24 h. Moreover, the MA and MT values obtained by 
UV-spectra comparison suggested that this peptide should 
be VV-hemorphin-7 (Table 1). This result was verified by 
the co.elution of this hemorphin.like peak with synthetic 
VV-hemorphin-7 at a retention time of approximatively 34 
rain (Fig. 3). This result was confirmed by Picotag amino 
acid analysis (Table 2). With regard to amino acid composi- 
tion, the weak hydrolysis of the VaI-Val peptide bond ac- 
counted for the 1.12 valine residues found per molecule of 
W-hemorphin-7. Fig. 4 shows the positive FAB-MS spec- 
trum of this hemorphin-like peak. Accurate relative molecular 
weight, deduced from the m/z value of (M + H) + by subtrac- 
tion of one mass unit for the attached proton is 1194. Accord- 
ing to these results and taking into account he known amino 
acid sequence of a and [3 bovine globins, it was clear that the 
composition found was only compatible with peptide of se- 
quence originating at Val residue 32 and extending to Phe-40 
in the [3-chain. In consequence, the amino acid composition 
determined for each hemorphin-like peak was in a good agree- 
ment with the spectra-comparison analysis and proved unam- 
Table 2 
Amino acid composition of hemorphin-like p ak isolated from 
B-24 h 
Amino acid Residues/molecule 
Asp 
Giu 0.94 
Ser 
Gly 
His 
Arg 0.96 
Thr 1.40 
Ala 
Pro !.17 
Tyr 1.00 
Val I. 12 
Met 
Cys 
I!¢ 
Leu 
Phe 1.07 
Lys 
Trp ND 
Amino acid composition analysis was similar for all samples (A-24 
h, B-24 h and C-24 h). Results are expressed in amino acid residues 
per molecule. 
ND: not determined. 
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Fig. 4. FAB mass pectrometry of hemorphin-like p ak. Positive ions were obtained by FAB mass pectrometry of hemorphin-like p ak. The 
abundant ion at 1195, designated asa molecular cation (M + H) +, suggests a molecular weight of ! 194. 
biguously that VV-hemorphin-7 (Val-Val-Tyr-Pro-Trp-Thr- 
Gin-Arg-Phe) was generated from globin by the macrophage 
acidic lysosomal enzymes. It can be noticed that no hemor- 
phin-like peak appeared in sample D-24 h (Fig. 2, D-24 h). 
All the chromatographic profiles were in good agreement with 
spectrophotometric measurements. 
In consequence, we may further suppose that the VV-he- 
morphin-7 formation was due to the cathepsin D action. 
More generally, the cathepsin D was probably responsible 
of the major proteolytic activity toward globin since no 
peak was detected when pepstatin A was added in the incuba- 
tion media (D-24 h). Control samples (TI to T3) were also 
injected and no peak was detected. 
Previous studies have demonstrated the ability of acidic 
proteases such as pepsin to generate biologically active VV- 
and LVV-hemorphin-7 from hemoglobin in vitro [2]. Concur- 
rently, some authors have found hemorphins in biological 
fluids [6]. Nevertheless, the generation of these bioactive pep- 
tides has never been described precisely as the result of a 
specific in rive proteolytic attack by cellular enzymes. In the 
present experiment, we investigated the possibility for macro- 
phage acidic proteases, and especially the pepsin-like nzyme 
cathepsin D, to liberate hemorphins from globin. It must be 
pointed out that LVV-hemorphin-7 has not been found in the 
resulting peptide mixture. Recently, we have demonstrated 
that during the peptic hydrolysis process of globin, LVV-he- 
morphin-7 disappeared when the level of VV-hemorphin-7 
increased. This study showed that LVV-hemorphin-7 was a 
precursor of VV-hemorphin-7 [26]. The results presented 
here suggest hat the same process hould be involved. 
in conclusion, this study gives evidence that macrophage 
enzyme(s) were able to generate at least one hemorphin 
from globin. The pH of this process and its inhibition by 
pepstatin A suggest that cathepsin D is the main enzyme in- 
volved. These results are in agreement with previous ugges- 
tions about the existence of precarsor(s) which could be pro- 
cessed to form biologically active peptides in vivo during 
states of enhanced phagocytosis and/or enzyme release by 
macrophage cells [25]. The actual pathway by which VV-he- 
morphin-7-peptide might be generated and involved physiolo- 
gically is presently not fully elucided. Some authors have al- 
ready demonstrated the potent role of hemorphins toward 
endorphins [15,16] and Angiotensin Converting Enzyme 
(ACE) [13,14]. These last authors suggested that these 
opioid-like peptides might act both on blood pressure regula- 
tion via ACE and on analgesic strength via opioid receptors 
during physiological and/or pathologic degradation of hemo- 
globin [l 3]. 
Therelbre, in the organism there could be an opioid system, 
represented by the "classical" opioid peptides (enkephalins, 
endorphins or dynorphins) and by hemorphins. Since several 
hemorphins have been found in rive [3,9] and characterized 
by their biological properties [13,17], it will be of great interest 
to find out all the metabolic pathways from hemoglobin to 
hemorphins. Moreover, Carraway et al. suggested the exist- 
ence of a putative ndogenous processing, similar to the re- 
nin-angiotensin system, which generates neurotensin- and en- 
kephalin-related peptides in blood circulation [27,28]. The in 
rive processing of plasma precursors may involve a pepsin- 
like activity releasing bioactive peptides from circulating sub- 
strates, as does pepsin in vitro [2] or macrophage acidic pro- 
teases as was suggested in the present work. Consequently, we 
could consider that such as system should be implicated in 
globin proteolysis in rive. 
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